8 published brand profiles in this category. Cite the individual brand profile for brand-specific facts.
Acerta Pharma - Acerta Pharma is a oncology brand headquartered in Redwood City, CA, founded in 2012.
Foghorn Therapeutics - Foghorn is pioneering a new class of medicines that treat serious disease by correcting abnormal gene expression. These precision therapeutic candidates target disease dependencies within the chromatin regulatory system, which means they change how genes turn on and off. Our therapies have the potential to be the next wave of medicines for cancer and other diseases.
Ignyta - Ignyta is an oncology company headquartered in San Diego, CA, founded in 2011.
Infinity Pharmaceuticals - Infinity Pharmaceuticals is an oncology company headquartered in Cambridge, MA, founded in 2000.
Karyopharm Therapeutics - Karyopharm is an innovation-driven pharmaceutical company whose core technology leverages the inhibition of nuclear export as a mechanism to treat
SpringWorks Therapeutics - We relentlessly pursue every possibility to create new cancer breakthroughs and power our approach with people who think hard, care hard, and act with urgency. %
Stemline Therapeutics - ORSERDU (elacestrant) is a selective estrogen receptor degrader (SERD) FDA approved for the treatment of postmenopausal women or adult men, with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Studies completed to date, including the positive results from the pivotal EMERALD trial, indicate that the compound has the potential for use as a single agent or in combination with other therapies fo
Taiho Oncology - There seems to be a slight problem with the URL you are trying to access. If you think you have reached this page in error, please double check the URL and try again. Or you may click this link to access the homepage.